Telo Genomics Expands its Strategic Collaboration with Mayo Clinic
Telo Genomics has expanded its collaboration with Mayo Clinic to include participation in their Physician Experience Program SMART, utilizing the TeloViewSMM prognostic test for smoldering multiple myeloma patients. The amendment also covers patient samples for blind validation of TeloViewNDMM, a test for newly diagnosed multiple myeloma patients, as a final step toward adding it as a Laboratory Developed Test. The TeloViewNDMM test aims to identify patients who will relapse on first-line therapy within a year or confirm treatment stability. The collaboration, initiated in 2020, has already led to the successful validation of TeloViewSMM, with results published in the American Journal of Hematology.
Telo Genomics ha ampliato la sua collaborazione con la Mayo Clinic per includere la partecipazione al loro Programma Esperienza per Medici SMART, utilizzando il test prognostico TeloViewSMM per pazienti con mieloma multiplo smoldering. L'emendamento copre anche i campioni dei pazienti per la validazione cieca del TeloViewNDMM, un test per pazienti con mieloma multiplo recentemente diagnosticati, come passo finale per aggiungerlo come Test Sviluppato in Laboratorio. Il test TeloViewNDMM mira a identificare i pazienti che avranno una recidiva durante la terapia di prima linea entro un anno o confermare la stabilità del trattamento. La collaborazione, avviata nel 2020, ha già portato alla validazione positiva di TeloViewSMM, con risultati pubblicati nell'American Journal of Hematology.
Telo Genomics ha ampliado su colaboración con la Mayo Clinic para incluir la participación en su Programa de Experiencia para Médicos SMART, utilizando la prueba pronóstica TeloViewSMM para pacientes con mieloma múltiple smoldering. La enmienda también cubre muestras de pacientes para la validación ciega de TeloViewNDMM, una prueba para pacientes recién diagnosticados con mieloma múltiple, como paso final para agregarla como Prueba Desarrollada en Laboratorio. La prueba TeloViewNDMM tiene como objetivo identificar a los pacientes que recaerán en la terapia de primera línea dentro de un año o confirmar la estabilidad del tratamiento. La colaboración, iniciada en 2020, ya ha llevado a la validación exitosa de TeloViewSMM, con resultados publicados en el American Journal of Hematology.
Telo Genomics는 Mayo Clinic과의 협업을 확장하여 의사 경험 프로그램 SMART에 참여하고 있으며, TeloViewSMM 예후 검사를 흡연 중 다발성 골수종 환자들에게 활용하고 있습니다. 수정된 협약은 신규 진단된 다발성 골수종 환자들을 위한 TeloViewNDMM 검사에 대한 블라인드 검증을 위한 환자 샘플을 포함합니다. 이는 실험실 개발 테스트로 추가하는 최종 단계입니다. TeloViewNDMM 검사는 1차 치료에서 1년 이내에 재발할 환자를 식별하거나 치료의 안정성을 확인하는 것을 목표로 합니다. 2020년에 시작된 이 협업은 이미 TeloViewSMM의 성공적인 검증으로 이어졌으며, 그 결과는 American Journal of Hematology에 발표되었습니다.
Telo Genomics a élargi sa collaboration avec la Mayo Clinic pour inclure la participation à leur programme d'expérience pour médecins SMART, utilisant le test pronostique TeloViewSMM pour les patients atteints de myélome multiple smoldering. L'amendement couvre également les échantillons de patients pour la validation à l'aveugle du TeloViewNDMM, un test pour les patients récemment diagnostiqués avec un myélome multiple, comme étape finale pour l'ajouter en tant que test développé en laboratoire. Le test TeloViewNDMM vise à identifier les patients qui vont rechuter lors du traitement de première ligne dans l'année ou à confirmer la stabilité du traitement. La collaboration, initiée en 2020, a déjà conduit à la validation réussie de TeloViewSMM, avec des résultats publiés dans l'American Journal of Hematology.
Telo Genomics hat die Zusammenarbeit mit der Mayo Clinic erweitert, um die Teilnahme an ihrem Programm zur Arzt-Erfahrung SMART einzuschließen, wobei der prognostische Test TeloViewSMM für Patienten mit schwelendem multiplem Myelom genutzt wird. Die Änderung umfasst auch Patientenproben zur blinden Validierung des TeloViewNDMM, einem Test für neu diagnostizierte multiple Myelom-Patienten, als letzten Schritt zur Hinzunahme als Laborentwickelter Test. Der TeloViewNDMM-Test zielt darauf ab, Patienten zu identifizieren, die innerhalb eines Jahres unter der Erstlinientherapie einen Rückfall erleiden oder die Stabilität der Behandlung zu bestätigen. Die 2020 gegründete Zusammenarbeit hat bereits zur erfolgreichen Validierung von TeloViewSMM geführt, mit Ergebnissen, die im American Journal of Hematology veröffentlicht wurden.
- TeloViewSMM test has completed validation and is now an approved Laboratory Developed Test
- Results of TeloViewSMM validation were published in American Journal of Hematology
- Expansion of Mayo Clinic collaboration strengthens clinical validation pathway
- None.
Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US. The amendment is an extension of the Telo Genomics relationship with Mayo Clinic to include their participation in Telo's Physician Experience Program SMART, using the Company's TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients. SMM is a precursor to active multiple myeloma.
The amendment also includes patient samples for the blind validation of TeloViewNDMM, Telo's test for newly diagnosed multiple myeloma (MM) patients. This validation is a final step to enable adding the TeloViewNDMM test as a Laboratory Developed Test (LDT) on Telo's CAP/ CLIA and ISO testing menu. The test is designed to identify newly diagnosed MM patients who will relapse on first line therapy within a year, or confirm that these patients are stable in remission on the treatment at the time of testing.
Telo's collaboration with the Mayo Clinic was initiated in 2020 for the development and validation of two prognostic tests for MM patients. The first test, TeloViewSMM, targeting the precursor stage of the disease SMM, and the second test, TeloViewNDMM, targeting patients newly diagnosed with full stage MM. Telo has completed the endpoints required for the validation of TeloViewSMM. The results were published in the American Journal of Hematology in Q2 of this year. This test is now an approved LDT on Telo's CAP/ CLIA and ISO 15189 testing menu.
"We are thrilled to announce the expansion of our collaboration agreement with Mayo Clinic. The collaboration has been invaluable thus far in the development and validation of Telo's flagship prognostic product TeloViewSMM," said Sherif Louis, Telo's President and CTO. "We are grateful for Mayo Clinic's participation in our SMART program as an effective step on the commercialization path of this validated CLIA test within our myeloma products portfolio. We look forward to taking TeloViewNDMM for newly diagnosed myeloma patients down the same development route by adding that test to our CLIA menu as an outcome of this amended collaboration."
About TeloViewSMM
The TeloViewSMM test is for SMM, a precursor to multiple myeloma. The test stratifies patients flagged with the elevated M-protein biomarker, into patients with high-risk to progress to the full stage of the MM disease, and those who are with stable form of the SMM stage. To date, this has been an important unmet need in the management of SMM patients. High risk SMM patients may benefit from immediate treatment intervention, with a possibility to achieve cure due to recent advancement in treatment regimens. Alternatively, low risk patients can be monitored using TeloViewSMM, without exposing these patients to unnecessary and debilitating treatment. Critically, TeloViewSMM can be used periodically as a non-invasive liquid biopsy test that can be performed using a simple blood draw. Recent demographic studies have shown that SMM prevalence provides a significant market opportunity with an estimated
About TeloViewNDMM:
Predicting NDMM patient response to first line therapy is an important clinical need. In current clinical practice, patients will remain on a specific treatment regimen until relapse and then be switched to an alternative regimen. The majority of NDMM patients relapse within the first 24 months with over
About TELO
Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Sherif Louis,
President & CTO
Telo Genomics
416-673-8487
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView® platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228303
FAQ
What is the purpose of Telo Genomics' TeloViewSMM test (TDSGF)?
What is the new TeloViewNDMM test from Telo Genomics (TDSGF) designed to do?
When did Telo Genomics (TDSGF) start its collaboration with Mayo Clinic?
